Interleukin 37 – a Novel Cytokine Therapy for Necrotizing Enterocolitis in the Preterm

白细胞介素 37 — 一种治疗早产儿坏死性小肠结肠炎的新型细胞因子疗法

• 批准号: nhmrc : GNT1138926
• 负责人: A/Pr Christiane Theda
• 金额: $ 74.88万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/interleukin-37-novel-enterocolitis-preterm/1348195
• 关键词: Interleukin; 37; Novel; Cytokine; Therapy

Neonatologists are adept at keeping extremely premature babies alive. But the price is a rising incidence of life-threatening diseases that include necrotising enterocolitis (NEC), a progressive and destructive intestinal inflammation that may require surgery, after which just 30% survive. We have created highly potent variants of the anti-inflammatory molecule interleukin 37 whose actions will improve our understanding of NEC pathogenesis and reveal their therapeutic potential in NEC.

新生儿学家擅长让极早产儿存活。但代价是危及生命的疾病发病率不断上升，其中包括坏死性小肠结肠炎 (NEC)，这是一种进行性、破坏性的肠道炎症，可能需要手术，手术后只有 30% 的患者存活。我们已经创建了抗炎分子白细胞介素 37 的高效变体，其作用将提高我们对 NEC 发病机制的理解并揭示其在 NEC 中的治疗潜力。